This Tiny Biotech is the Investment of a Lifetime

Biotech's Next Big Giant?... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Unsubscribe A message from i2i Marketing    Dear Reader, A few years from now... scars may be a thing of the past. Just imagine...children of future generations may never even know what a scar is. It could be completely foreign to them. Like smallpox. And polio. That's how profound this tiny biotech's treatment could be. But this goes far beyond just scars. Up to 45% of the deaths in the world from fibrosis could potentially be prevented... Type 1 diabetes could be cured and wiped off the planet. Alopecia and other autoimmune disorders... gone for good. In what could be just weeks from now, this tiny company is poised to go public on the NASDAQ. And it won't be long before this treatment could be found in every hospital and doctor's office around the country. Right now you have a chance to get in before the public... If you want to take advantage of this limited window… it may still be open. Best, Editor This message is a PAID ADVERTISEMENT for BirchBioMed Inc. (Reg A+) from i2i Marketing Group, LLC. StockEarnings, Inc. has received a fixed fee of $5,000 from i2i Marketing Group, LLC. for multiple Dedicated Email Sends, Newsletter Sponsorships, SMS Sends, and Banner Display Ads between November 18, 2024 and November 28, 2024. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BirchBioMed Inc. (Reg A+) or i2i Marketing Group, LLC. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BirchBioMed Inc. (Reg A+) on BirchBioMed website for additional information about the relationship between i2i Marketing Group, LLC. and BirchBioMed Inc. (Reg A+). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com